Aphaia Pharma to Participate in Panel Discussion at the 1st Annual BioPharma Obesity Innovation Forum in San Francisco
19. Dezember 2024 08:30 ET
|
Aphaia Pharma
ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore...
Aphaia Pharma to Participate in a Panel Discussion at the 1st Annual Obesity & Metabolic Innovation Forum
25. November 2024 08:00 ET
|
Aphaia Pharma
ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore...
Aphaia Pharma Announces Positive Results from Phase 2 Trial Evaluating its Lead Drug Formulation for Prediabetes Treatment
20. Juni 2024 08:30 ET
|
Aphaia Pharma
Primary endpoint met, showing that APHD-012 improves glucose tolerance in individuals with a pathological oral glucose tolerance test (OGTT) after 6 weeks of administrationThe results provide...
Aphaia Pharma Completes Enrollment in Arm 2 of Phase 2 Trial in Individuals with Obesity
13. Juni 2024 08:30 ET
|
Aphaia Pharma
Enrollment has been completed for the last four cohorts evaluating the contribution of circadian effects in weight loss treatment using Aphaia’s formulationTopline data anticipated in Q3 and Q4 2024...
Aphaia Pharma Provides Enrollment and Protocol Update for Phase 2 Trial in Individuals with Obesity
25. April 2024 08:30 ET
|
Aphaia Pharma
Enrollment has been completed for the first two cohorts evaluating a once-daily 12g dose of its oral glucose formulation (APHD-012)The company is expanding its trial protocol to further explore the...
Aphaia Pharma to Participate in a Panel Discussion at the 10th LSX World Congress
16. April 2024 08:30 ET
|
Aphaia Pharma
ZUG, Switzerland and SAN JUAN, Puerto Rico and TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore...
Aphaia Pharma Announces Dosing of First Patient in its Phase 2 Trial Evaluating its Lead Candidate APH-012 for Prediabetes
25. April 2023 08:30 ET
|
Aphaia Pharma
ZUG, Switzerland and SAN JUAN, Puerto Rico, April 25, 2023 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous...
Aphaia Pharma to Participate in the LSX Leaders Inv€$tival Showcase
07. November 2022 08:30 ET
|
Aphaia Pharma
ZUG, Switzerland, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage company harnessing precision-targeted drug formulations to restore endogenous endocrine balance for the treatment...
Aphaia Pharma Announces Enrollment of First Patient in Phase 2 Study of APH-012 for Chronic Weight Management in Individuals with Obesity
27. Oktober 2022 08:30 ET
|
Aphaia Pharma
ZUG, Switzerland, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Aphaia Pharma, a clinical-stage biopharmaceutical company harnessing precision-targeted drug delivery technology for the treatment and prevention...